BACKGROUND: The anti-human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves the outcome in patients with HER2-positive metastatic breast cancer. However, most cases of advanced disease eventually progress. Pertuzumab, an anti-HER2 humanized monoclonal antibody that inhibits receptor dimerization, has a mechanism of action that is complementary to that of trastuzumab, and combination therapy with the two antibodies has shown promising activity and an acceptable safety profile in phase 2 studies involving patients with HER2-positive breast cancer. METHODS: We randomly assigned 808 patients with HER2-positive metastatic breast cancer to receiveplacebo plus trastuzumab plus docetaxel (control group) or pertuzumab plus trastuzumab plus docetaxel (pertuzumab group) as first-line treatment until the time of disease progression or the development of toxic effects that could not be effectively managed. The primary end point was independently assessed progression-free survival. Secondary end points included overall survival, progression-free survival as assessed by the investigator, the objective response rate, and safety. RESULTS: The median progression-free survival was 12.4 months in the control group, as compared with 18.5 months in the pertuzumab group (hazard ratio for progression or death, 0.62; 95% confidence interval, 0.51 to 0.75; P<0.001). The interim analysis of overall survival showed a strong trend in favor of pertuzumab plus trastuzumab plus docetaxel. The safety profile was generally similar in the two groups, with no increase in left ventricular systolic dysfunction; the rates of febrile neutropenia and diarrhea of grade 3 or above were higher in the pertuzumab group than in the control group. CONCLUSIONS: The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT00567190.).
RCT Entities:
BACKGROUND: The anti-human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves the outcome in patients with HER2-positive metastatic breast cancer. However, most cases of advanced disease eventually progress. Pertuzumab, an anti-HER2 humanized monoclonal antibody that inhibits receptor dimerization, has a mechanism of action that is complementary to that of trastuzumab, and combination therapy with the two antibodies has shown promising activity and an acceptable safety profile in phase 2 studies involving patients with HER2-positive breast cancer. METHODS: We randomly assigned 808 patients with HER2-positive metastatic breast cancer to receive placebo plus trastuzumab plus docetaxel (control group) or pertuzumab plus trastuzumab plus docetaxel (pertuzumab group) as first-line treatment until the time of disease progression or the development of toxic effects that could not be effectively managed. The primary end point was independently assessed progression-free survival. Secondary end points included overall survival, progression-free survival as assessed by the investigator, the objective response rate, and safety. RESULTS: The median progression-free survival was 12.4 months in the control group, as compared with 18.5 months in the pertuzumab group (hazard ratio for progression or death, 0.62; 95% confidence interval, 0.51 to 0.75; P<0.001). The interim analysis of overall survival showed a strong trend in favor of pertuzumab plus trastuzumab plus docetaxel. The safety profile was generally similar in the two groups, with no increase in left ventricular systolic dysfunction; the rates of febrile neutropenia and diarrhea of grade 3 or above were higher in the pertuzumab group than in the control group. CONCLUSIONS: The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT00567190.).
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: M X Sliwkowski; G Schaefer; R W Akita; J A Lofgren; V D Fitzpatrick; A Nuijens; B M Fendly; R A Cerione; R L Vandlen; K L Carraway Journal: J Biol Chem Date: 1994-05-20 Impact factor: 5.157
Authors: Vicente Valero; John Forbes; Mark D Pegram; Tadeusz Pienkowski; Wolfgang Eiermann; Gunter von Minckwitz; Henri Roche; Miguel Martin; John Crown; John R Mackey; Pierre Fumoleau; Janusz Rolski; Zrinka Mrsic-Krmpotic; Agnieszka Jagiello-Gruszfeld; Alessandro Riva; Marc Buyse; Henry Taupin; Guido Sauter; Michael F Press; Dennis J Slamon Journal: J Clin Oncol Date: 2010-11-29 Impact factor: 44.544
Authors: José Baselga; Karen A Gelmon; Shailendra Verma; Andrew Wardley; Pierfranco Conte; David Miles; Giulia Bianchi; Javier Cortes; Virginia A McNally; Graham A Ross; Pierre Fumoleau; Luca Gianni Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544
Authors: Chia C Portera; Janice M Walshe; Douglas R Rosing; Neelima Denduluri; Arlene W Berman; Ujala Vatas; Margarita Velarde; Catherine K Chow; Seth M Steinberg; Diana Nguyen; Sherry X Yang; Sandra M Swain Journal: Clin Cancer Res Date: 2008-05-01 Impact factor: 12.531
Authors: Werner Scheuer; Thomas Friess; Helmut Burtscher; Birgit Bossenmaier; Josef Endl; Max Hasmann Journal: Cancer Res Date: 2009-12-15 Impact factor: 12.701
Authors: Sridhar K Rabindran; Carolyn M Discafani; Edward C Rosfjord; Michelle Baxter; M Brawner Floyd; Jonathan Golas; William A Hallett; Bernard D Johnson; Ramaswamy Nilakantan; Elsebe Overbeek; Marvin F Reich; Ru Shen; Xiaoqing Shi; Hwei-Ru Tsou; Yu-Fen Wang; Allan Wissner Journal: Cancer Res Date: 2004-06-01 Impact factor: 12.701
Authors: Alexandra Canonici; Zulfiqar Qadir; Neil T Conlon; Denis M Collins; Neil A O'Brien; Naomi Walsh; Alex J Eustace; Norma O'Donovan; John Crown Journal: Invest New Drugs Date: 2018-02-02 Impact factor: 3.850